


Application S. No. 10/762,444

Filed: January, 21, 2004


Page 2 of 15

**Listing of claims:**


1. (Currently amended) A drug product for the treatment of amyloidosis in a mammal suffering therefrom, comprising a container labeled or accompanied by a label indicating that the drug product is for the treatment of amyloidosis, the container containing one or more dosage units each comprising at least one pharmaceutically acceptable excipient and, as an active ingredient, an isolated pure compound ~~selected from the group consisting of the compounds of formula A, formula B, formula C, formula D, and formula E:~~




Formula A




Formula B



Formula C



Formula D



Formula E

where:

~~R is selected from the group consisting of hydrogen, 2,3-dihydroxybenzoyl, 3,4-dihydroxybenzoyl, 2,3,4-trihydroxybenzoyl, and 3,4,5-trihydroxybenzoyl;~~

~~R' is hydrogen or OH; R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, halogen, C<sub>1-6</sub> alkyl and C<sub>1-6</sub> alkoxy, each alkyl and alkoxy group optionally substituted with up to 5 halogen atoms and non-interfering substituents;~~

X is selected from hydrogen and the group consisting of

(a) hydroxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, and cycloamino,

(b) C<sub>1-22</sub> alkyl, C<sub>1-22</sub> alkoxy, C<sub>1-22</sub> alkylthio, and C<sub>1-22</sub> alkylcarboxyl, each optionally substituted with 1 to 5 moieties selected from the group consisting of halogen, hydroxy, mercapto, amino, nitro, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, and C<sub>1-6</sub> alkylcarboxyl,

(c) aromatic and heteroaromatic groups substituted with 2 or 3 adjacent hydroxy groups, and optionally substituted with 1 to 5 non-interfering substituents.

CAJD-528239v2

Application S. No. 10/762,444

Filed: January, 21, 2004

Page 3 of 15

(d) sugars, optionally substituted with one or more anionic groups selected from sulfate, phosphate, phosphonate, carboxylate, and sulfonate groups, and

(e) peptides and peptide derivatives, and

(f)  $\text{C}(\text{O})\text{R}_3$  and  $\text{C}(\text{O})\text{OR}_4$ , where  $\text{R}_3$  is selected from the group consisting of (a) through (e) above; and Y is hydrogen, hydroxy,  $\text{C}_{1-6}$  alkoxy, benzyl, where the phenyl group is optionally substituted with 1 to 3 substituents selected from halo and  $\text{C}_{1-6}$  alkyl, or  $\text{OSO}_2\text{R}_4$ , where  $\text{R}_4$  is  $\text{C}_{1-6}$  alkyl or phenyl optionally substituted with 1 to 3 substituents selected from halo and  $\text{C}_{1-6}$  alkyl; and

~~the group of compounds consisting of acetoin, actinorhedine, alizarin, alizarin blue, alizarin orange, alizarinsulfonic acid, alkannin, anthragallol, anthralin, anthraquinin, anthraquinone, apigenin, apigetin, apiose, baicalein, baptigenin, 1,2,4-benzenetriol, bestrocyoidin, carbideopa, carminic acid, carubicin, cellobiose, centaurein, chloranilic acid, chendresine, chromotrope 2B, chromotropic acid, chrysanthemic acid, chrysarobin, chrysanthemic acid, cichoriin, citratinic acid, citromycetin, collinemycin, curvularia, cyanidin, cyanidin 3-glucoside, cyanidin 3-rhamnoglucoside, cyanidin 3,5-diglucoside, cyanidin 3-sophoroside, daphnetin, datiscetin, daunorubicin, delphinidin, deoxyepinephrine, diosmetin, diosmin, diosmetidin, depa, dopamine, doxorubicin, droxidopa, ephinephrine A, embelin, emodin, ergoflavin, eriodictyol, esculetin, fenoldopam, fomecin A, fomecin B, fraxetin, fraxin, fredericamycin A, fumigatin, fusarubin, fusicin, fustin, galangin, gallocyanine, gardenin A, gardenin B, gardenin C, gardenin D, gardenin E, genistein, gentisin, granatin, guamecycline, hennetatin, hydroxysophorobioside, hydroxysophoricoside, icariin, isouquereitin, kaempferol, kermesic acid, laccate acid A, laccate acid B, laccate acid C, laccate acid D, leucocyanidin, luteolin, maeurin, menegalin, methylenedigalllic acid, merin, oosporein, phenicin, phloroglucide, puberulic acid, puberulonic acid, purpurin, purpurogallin, quercetagetin, quercimarin, quinalizarin, quinic acid, resacetophenone, rhamnetin, rhein, rhodizonic acid, rhodomyein A, rhodomyein B, robinin, ruberythric acid, rufigallol, rutin, scutellarein, tannic acid, tetraquinone, tiron, troxerutin, and tunichrome B1, but excluding pyrogallol, and the pharmaceutically acceptable salts thereof.~~

2. (Original) The drug product of claim 1 containing only one active ingredient compound.


Application S. No. 10/762,444

Filed: January, 21, 2004


Page 4 of 15

3. (Original) The drug product of claim 2, wherein the label indicates that the drug product is for the treatment of Alzheimer's disease.


4. (Currently amended) A method of treating a mammal suffering from a Lewy body disease or Parkinson's disease characterized by  $\alpha$ -synuclein fibril formation, comprising administration to the mammal of a therapeutically effective amount of an isolated pure compound selected from the group consisting of the compounds of formula A, formula B, formula C, formula D, and formula E:




Formula A




Formula B



Formula C



Formula D



Formula E

where:

R is selected from the group consisting of hydrogen, 2,3-dihydroxybenzoyl, 3,4-dihydroxybenzoyl, 2,3,4-trihydroxybenzoyl, and 3,4,5-trihydroxybenzoyl;

R' is hydrogen or OR'; R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, halogen, C<sub>1-6</sub> alkyl and C<sub>1-6</sub> alkoxy, each alkyl and alkoxy group optionally substituted with up to 5 halogen atoms and non-interfering substituents;

X is selected from hydrogen and the group consisting of

(a) hydroxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, and cycloamino,

(b) C<sub>1-22</sub> alkyl, C<sub>1-22</sub> alkoxy, C<sub>1-22</sub> alkylthio, and C<sub>1-22</sub> alkylcarboxyl, each optionally substituted with 1 to 5 moieties selected from the group consisting of halogen, hydroxy, mercapto, amino, nitro, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, and C<sub>1-6</sub> alkylcarboxyl,

(c) aromatic and heteroaromatic groups substituted with 2 or 3 adjacent hydroxy groups, and optionally substituted with 1 to 5 non-interfering substituents,

Application S. No. 10/762,444

Filed: January, 21, 2004

Page 5 of 15

(d) sugars, optionally substituted with one or more anionic groups selected from sulfate, phosphate, phosphonate, carboxylate, and sulfonate groups, and

(e) peptides and peptide derivatives, and

(f)  $\text{C}(\text{O})\text{R}_3$  and  $\text{C}(\text{O})\text{OR}_3$ , where  $\text{R}_3$  is selected from the group consisting of (a) through (e) above; and  $\text{Y}$  is hydrogen, hydroxy,  $\text{C}_{1-6}$ -alkoxy, benzoyloxy, where the phenyl group is optionally substituted with 1 to 3 substituents selected from halo and  $\text{C}_{1-6}$ -alkyl, or  $\text{OSO}_2\text{R}_4$ , where  $\text{R}_4$  is  $\text{C}_{1-6}$ -alkyl or phenyl optionally substituted with 1 to 3 substituents selected from halo and  $\text{C}_{1-6}$ -alkyl; and

~~the group of compounds consisting of acetin, actinorhedine, alizarin, alizarin blue, alizarin orange, alizarinsulfonic acid, alkannin, anthragallol, anthralin, anthrarebin, anthrauin, apigenin, apigetrin, apiose, baicalin, baptogenin, 1,2,4-benzenetriol, bestrocidin, carbidopa, carminic acid, carubicin, cecilebiscetin, centaurein, chloranilic acid, chondrosine, chromotrope 2B, chremotrope acid, chrysanthemic acid, chrysarobin, chrysirin, chrysophanic acid, cichorin, citratinic acid, citromyecin, collinomycin, curvularin, cyanidin, cyanidin 3-glucoside, cyanidin 3-rhamnoglucoside, cyanidin 3,5-diglucoside, cyanidin 3-sophoroside, daphnetin, datiscetin, daunorubicin, delphinidin, deoxyepinephrine, diesmetin, diosmin, dioxethedrine, dopa, dopamine, doxorubicin, droxidopa, echinochrome A, embelin, emodin, ergoflavin, eriodietyl, esculin, fenzodopam, fomecin A, fomecin B, fraxetin, fraxin, fredericamycin A, fumigatin, fusarubin, fuscin, fustin, galangin, gallein, gallocyanine, gardenin A, gardenin B, gardenin C, gardenin D, gardenin E, genistein, gentisin, granaticein, guamecycline, hemanthrin, hydroxysephorobioside, hydroxysephoricoside, iariin, isouqueretin, kaempferol, kermesic acid, laeccic acid A, laeccic acid B, laeccic acid C, laeccic acid D, leucocyanidin, luteolin, maclurin, menegaril, methylenedigallic acid, morin, oosporein, phenicin, phloroglucide, puberulic acid, puberulonic acid, purpurin, purpurogallin, quercetagetin, quercimarin, quinalizarin, quinic acid, resistomycin, rhamnetin, rhein, rhodizonic acid, rhodomycin A, rhodomycin B, robinin, ruberythric acid, rufigallol, rutin, scutellarein, tannic acid, tetroquinone, tiron, troxerutin, and tanichrome B1, but excluding pyrogallol, and the pharmaceutically acceptable salts thereof.~~

5. (Original) The method of claim 4 where only one such compound is administered.

6. (Original) The method of claim 5 where the mammal is a human.

7. (Cancelled).


Application S. No. 10/762,444

Filed: January, 21, 2004


Page 6 of 15

8. (Currently amended) The method of claim 7 claim 1, where the disease is Parkinson's disease.


9. (Currently amended) A drug product for the treatment of a Lewy body disease or Parkinson's disease characterized by  $\alpha$ -synuclein fibril formation in a mammal suffering therefrom, comprising a container labeled or accompanied by a label indicating that the drug product is for the treatment of a Lewy body disease or Parkinson's disease characterized by  $\alpha$ -synuclein fibril formation, the container containing one or more dosage units each comprising at least one pharmaceutically acceptable excipient and, as an active ingredient, an isolated pure compound selected from the group consisting of the compounds of formula A, formula B, formula C, formula D, and formula E:




Formula A




Formula B



Formula C



Formula D



Formula E

where:

R is selected from the group consisting of hydrogen, 2,3-dihydroxybenzoyl, 3,4-dihydroxybenzoyl, 2,3,4-trihydroxybenzoyl, and 3,4,5-trihydroxybenzoyl;

R' is hydrogen or OH; R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, halogen, C<sub>1-6</sub> alkyl and C<sub>1-6</sub> alkoxy, each alkyl and alkoxy group optionally substituted with up to 5 halogen atoms and non-interfering substituents;

X is selected from hydrogen and the group consisting of

(a) hydroxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, and cycloamino.

Application S. No. 10/762,444

Filed: January, 21, 2004

Page 7 of 15

(b)  $C_{1-22}$  alkyl,  $C_{1-22}$  alkoxy,  $C_{1-22}$  alkylthio, and  $C_{1-22}$  alkylcarboxyl, each optionally substituted with 1 to 5 moieties selected from the group consisting of halogen, hydroxy, mercapto, amino, nitro,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, and  $C_{1-6}$  alkylcarboxyl,

(c) aromatic and heteroaromatic groups substituted with 2 or 3 adjacent hydroxy groups, and optionally substituted with 1 to 5 non-interfering substituents,

(d) sugars, optionally substituted with one or more anionic groups selected from sulfate, phosphate, phosphonate, carboxylate, and sulfonate groups, and

(e) peptides and peptide derivatives, and

(f)  $C(O)R_3$  and  $C(O)OR_3$ , where  $R_3$  is selected from the group consisting of (a) through (e) above; and  $Y$  is hydrogen, hydroxy,  $C_{1-6}$  alkoxy, benzyloxy, where the phenyl group is optionally substituted with 1 to 3 substituents selected from halo and  $C_{1-6}$  alkyl, or  $OSO_2R_4$ , where  $R_4$  is  $C_{1-6}$  alkyl or phenyl optionally substituted with 1 to 3 substituents selected from halo and  $C_{1-6}$  alkyl; and

the group of compounds consisting of acetacetin, actinorhodine, alizarin, alizarin blue, alizarin orange, alizarinsulfonic acid, alkannin, anthraagelol, anthralin, anthracabin, anthraquin, apigenin, apigenin, apiose, baicalin, baptogenin, 1,2,4-benzeneetriol, bestrocydin, carbideps, carminic acid, carubiein, cellobiose, centaurein, chloranilic acid, chondresine, chromotrope 2B, chromotrope acid, chrysanthemic acid, chrysarobin, chrysin, chrysophanic acid, eichornin, etrazinic acid, citromyecin, collinomycin, curvularin, cyanidin, cyanidin 3-glucoside, cyanidin 3-rhamnoglucoside, cyanidin 3,5-diglucoside, cyanidin 3-sophoreside, daphnetin, datiscetin, daunorubicin, delphinidin, deoxyepinephrine, diosmetin, diosmin, dioxethedrine, depa, dopamine, doxorubicin, droxidopa, echinochrome A, embelin, emedin, ergoflavin, eriodictyol, esculetin, fenoldopam, fomecin A, fomecin B, fraxetin, fraxin, fredericamycin A, fumigatin, fusarubin, fustin, galangin, gallein, gallocyanine, gardenin A, gardenin B, gardenin C, gardenin D, gardenin E, genistein, gentisin, granatinein, guamecyeline, hemanthein, hydroxysophorobioside, hydroxysopeharioside, icariin, isoquercetin, kaempferol, kermesic acid, laccate acid A, laccate acid B, laccate acid C, laccate acid D, leucocyanidin, luteolin, maeluin, menegaril, methylenedigallie acid, merin, oosporein, phenicin, phloroglucide, puberulic acid, puberulonic acid, purpurin, purpurogallin, quercestragin, quercimitrin, quinalizarin, quinic acid, resistomycin, rhamnetin, rhein, rhodizonic acid, rhodomyein A, rhodomyein B, robinin,

Application S. No. 10/762,444

Filed: January, 21, 2004

Page 8 of 15

~~ruberythric acid, rutigallol, rutin, scutellarein, tannic acid, tetraquinone, tiron, triceratin, and unichrome B1, but excluding pyrogallol, and the pharmaceutically acceptable salts thereof.~~

10. (Original) The drug product of claim 9 containing only one such compound.

11. (Original) The drug product of claim 10 indicated for the treatment of Parkinson's disease.